NCT Number: NCT00404001
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
The primary objectives of this study are to evaluate the safety of MD-0727 in patients with primary hypercholesterolemia and to determine the low density lipoprotein cholesterol (LDL-C) lowering effect and dose-response of MD-0727 in patients with primary hypercholesterolemia.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Microbia Investigational Site, Birmingham, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patient is male or non-pregnant, non-breastfeeding female, at least 18 years of age
- Patient must agree to use contraception and/or birth control if sexually active
- Patient may not be on lipid-lowering therapies at least 6 weeks prior to study and must have a fasting LDL-C 130 mg/dl or greater at Screening
- Patient must have an average of two fasting LDL-C measures greater than/equal to 130 mg/dl but less than/equal to 210 mg/dl with a difference in the two measures less than/equal to 15%. Patient may not have a fasting serum triglyceride less than 300 mg/dl during Pre-treatment Period
- Patient's BMI must be greater than/equal to 18.5 but less than 35.0 at Screening
- Patient must complete a physical exam, 12-lead ECG, and other laboratory tests (including pregnancy test) with no clinically-significant findings prior to the first dose of study medication
- Patient agrees to comply with the TLC diet
- Patient completes a 6-week washout of previous lipid-lowering medication including over-the-counter products
Exclusion criteria
- Patient has a medical condition that is prohibited per protocol or a condition that the Investigator believes may limit the patient's ability to participate in the study
- Patient has a TSH level >1.5 X the upper limit of normal
- Patient has history of cardiovascular or coronary artery disease, uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins, or patient has history of NYHA Class III or IV congestive heart failure
- Patient is diabetic or presents with fasting blood glucose greater than/equal to 126 mg/dl at any time prior to randomization
- Patient has uncontrolled hypertension with a systolic blood pressure greater than/equal to 180 mm Hg or diastolic blood pressure greater than/equal to 110 mmg Hg at two study visits prior to the first dose of study medication
- Patient has a 10-year CHD risk of > 20%
- Patient has ALT or AST > 1.5 X the upper limit of normal prior to randomization
- Patient has a history of alcohol or drug abuse within 12 months of Screening
- Patient has used a prohibited medication (per protocol) during the 14-day Pre-treatment Visit
Treatment and study plan
Primary outcomes
-
Low density lipoprotein cholesterol (LDL-C)
Secondary outcomes
-
Total cholesterol
Sponsors and collaborators
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Registry information
Official study title
A Phase 2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study of the Safety and Efficacy of Orally Administered MD-0727 in Patients With Primary Hypercholesterolemia
Important dates
- Study start
- 2006
- Study completion
- 2007
- First posted
- Nov 27, 2006
- Registry last updated
- Oct 1, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
NCT00001154
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemia
Bethesda, Maryland, United States
View Trial DetailsGenetic Influences on Statin Blood Concentrations in African Americans
NCT01569867
Dyslipidemia, Dyslipidemias
Columbus, Ohio, United States
View Trial DetailsEffects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI
NCT03718286
Acute Coronary Syndrome, Cardiovascular Diseases
Hamilton, Ontario, Canada
View Trial DetailsEvaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
NCT02957682
Dyslipidemias, Hypercholesterolemia
Auburn, Alabama, United States
View Trial Details